TickerTalks
Browse all tickers →
TickerTalks›$BNTX
BNBNTX

BioNTech SE

$BNTX·$24B·Biotechnology·Healthcare
$102.08-8.4%YTD-5.3%1Y+0.1%
Mentions · last 7 days
2026-08-21: 43 posts2026-08-22: 90 posts2026-08-23: 35 posts2026-08-24: 18 posts412+33%
Price updated 3d ago·X counts updated 7d ago
BNBNTX
$BNTXBioNTech SE
$102.08-8.37%412 posts+33%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $BNTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventSelling offAI verdict · as of 2026-08-29

Falling on heavy selling — points lower unless it turns around.

BioNTech's XFG COVID approval was landing, then the colorectal cancer vaccine trial just failed — cash cushion is huge, but the pipeline just took a real hit.

BioNTech is the German mRNA vaccine developer that co-owns Pfizer's COVID franchise and is investing heavily into cancer immunotherapy. The setup pivoted from a bullish catalyst-play into a broken pipeline read overnight.

  • The trial failure is the load-bearing negative: today's -8.4% drop follows termination of BNT122-01, the colorectal cancer vaccine trial that Roche helped build — a real setback for the personalized-mRNA-oncology thesis that the whole $110 breakout narrative depended on, and Moderna dropped -6% on the read-through.
  • The COVID franchise still supports the balance sheet: FDA approval of the XFG-adapted Comirnaty COVID-19 vaccine with Pfizer keeps the franchise economics flowing, Q4 2025 revenue was ~$899M at 63% gross margin, and BNTX still holds ~$19.4B of cash against a ~$27.5B market cap — the pipeline funding is not the issue.
  • The pipeline math is now under pressure: ~$8B of enterprise value is priced around the pipeline (personalized cancer vaccines, PD-1/VEGF bispecifics), and today's colorectal miss means the sell side has to reprice how much of that is durable — the November 3 print is the next referee for how much the trial failure reshapes forward guidance.

The setup rests on the November 3 Q3 print plus any BNT122-01-related pipeline commentary. A read that the remaining oncology pipeline (esobio, VEGF bispecifics) is intact plus reiterated COVID franchise guidance is what stops the break-down; another pipeline setback or a Roche-partnership renegotiation would extend the drift toward the low-$90s. The $19.4B cash cushion means this is a valuation reset, not a solvency risk.

Differs from X sentimentThe bullish X read (before today's news) on the FDA approval of the XFG-adapted Comirnaty COVID-19 vaccine, the $110 breakout on MRNA cancer-vaccine sympathy, and the $27.5B market cap / $19.4B cash / $8B pipeline framing was factually right — but the crowd is not yet processing today's BNT122-01 trial termination in colorectal cancer, which directly undercuts the "overlooked cancer play" thesis and drove the -8% drop. The bull case now needs re-underwriting.

What to watch: The November 3 Q3 earnings — need read that the remaining oncology pipeline (esobio, VEGF bispecifics) is intact, reiterated COVID franchise guidance, and any commentary on the BNT122-01 termination's read-through. Another pipeline setback extends the drift toward the low-$90s; a clean remaining-pipeline update plus a fresh cancer-vaccine data readout reverses the break-down.

On the calendar: 2026-11-03 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment30 posts analyzed · as of 2026-08-30

The mood is unsettled after BioNTech terminated its Phase 2 autogene cevumeran trial in resected colorectal cancer following a DSMB flag on numerical survival imbalance. Bulls counter with FDA approval of the XFG-adapted COVID vaccine, a mesothelioma readout coming, and a $27B market cap sitting on roughly $19B of cash leaving only $8B for a broad pipeline. The colorectal setback dominates the narrative.

Read the AI verdict + X sentiment for $BNTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

mRNA biotech known for Pfizer/BioNTech COVID vaccine, now advancing a broad cancer immunotherapy pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $BNTX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $BNTX

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-15.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-7.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-52.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-6.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
77.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-3.70$-2.40-54.3%
Q1 2026May 5, 2026$-2.43$-2.54+4.4%
Q4 2025Mar 10, 2026$-1.44$-0.22-556.7%
Q3 2025Nov 3, 2025$-0.14$-1.12+87.5%
Next earningsTue, Nov 3·consensus EPS $0.86

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$120.0M-34.3%-63.2%-560%$-2.14$-485.7M
Q4 FY25$898.9M-24.5%63.3%-25.7%$-1.23$237.7M
Q3 FY25$1.5B+22.0%90.2%-3.1%$-0.12$811.1M
Q2 FY25$260.8M+102.6%70.7%-192%$-1.60$700.0M

Forward consensus

5-year forecast · up to 14 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.2B$2.1B – $2.2B-$4.49-$4.72 – -$4.2513
FY27$2.2B$1.9B – $2.6B-$4.70-$6.16 – -$3.2512
FY28$2.6B$1.4B – $3.3B-$4.41-$9.39 – -$0.6914
FY29$2.2B$1.8B – $2.7B-$4.76-$6.12 – -$3.449
FY30$2.6B$2.0B – $3.2B-$3.82-$4.91 – -$2.7613

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.51%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+7.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+4.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellApr 22Sierk PoettingCOO50.0K sh$5.5M
+ 5 other (5 awards) in window

See when $BNTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJun 263
AI summary

Iris Katharina Low-Friedrich was appointed to BioNTech SE's supervisory board effective June 26, 2026, and reports no securities beneficially owned. Routine initial Section 16 disclosure for the German mRNA vaccine company's new board member.

3New insider — initial holdingsJun 263
AI summary

Susanne Schaffert was appointed to BioNTech SE's supervisory board effective June 26, 2026, and reports no securities beneficially owned. Same routine initial Section 16 disclosure as the companion filing; two new supervisory board members were added to BioNTech on the same date.

3/ANew insider — initial holdingsApr 133/A
AI summary

Ugur Sahin, co-founder and CEO of BioNTech SE (BNTX), filed an amended Form 3/A on March 18, 2026, correcting or supplementing his initial ownership disclosure. Sahin is a major beneficial owner and the scientific and commercial leader of the mRNA vaccine company based in Mainz, Germany. The amendment updates the record of his initial holdings.

3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
+ 32 other (19 6-Ks · 8 3s · 2 20-F/As · 2 13Gs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And Moreseekingalpha.com·3d agoBioNTech Kills a Cancer Trial Roche Helped Buildgurufocus.com·3d agoBioNTech Stock Dips After BNT122-01 Trial Terminationbenzinga.com·3d agoBioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat247wallst.com·3d agoBioNTech to terminate mid-stage trial of mRNA cancer vaccinereuters.com·3d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport